CMS to blame for Part D marketing lapses?

14 September 2008

The USA's Centers for Medicare and Medicaid Services (CMS) has been criticized for its "near-total failure," according to Senate Finance Committee Chairman, Max Baucus (Democrat, Montana), to provide appropriate sample documents to health care insurers in the run up to the launch of the Medicare Part D prescription drug benefit in 2006 (Marketletters passim).

Although a CMS spokesman told the Associated Press that most of the problems have been resolved, following an Office of the Inspector General report, it also emerged that many marketing materials were not reviewed by the CMS within 18 months.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight